MedPacto's Pancreatic Cancer Combination Therapy Poster Selected for AACR Pancreatic Cancer Conference

Vactosertib-FOLFOX Combination Therapy in First-Line Treatment Failure Pancreatic Cancer Patients, Phase 1b Clinical Trial
Objective Response Rate of 23.1%
Overall Survival (OS) Data to Be Released

[Asia Economy, reporter Park Hyungsoo] MedPacto, a company specializing in the development of innovative new drugs based on biomarkers, announced on July 27 that interim clinical data for its combination therapy using Vactosertib for pancreatic cancer has been selected for poster presentation at the AACR Special Conference on Pancreatic Cancer.

The AACR Special Conference on Pancreatic Cancer, which will be held in Boston, USA, from August 13 to 16, will feature the release of various clinical data related to pancreatic cancer treatment.

MedPacto will present interim data from its Phase 1b (investigator-initiated) clinical trial of the Vactosertib-FOLFOX combination therapy for pancreatic cancer in a poster session. The data to be presented includes overall survival (OS) data in addition to the interim Phase 1b data on the FOLFOX combination therapy that was previously disclosed at the American Society of Clinical Oncology (ASCO) in June.

According to the interim Phase 1b data on the Vactosertib-FOLFOX combination therapy for pancreatic cancer disclosed at ASCO, the objective response rate (ORR) was 23.1% among 13 patients who received 200mg of Vactosertib twice daily. Additionally, 38.5% of patients achieved stable disease (SD), meaning the tumor did not increase in size. The clinical benefit rate was 61.5%. The median progression-free survival (mPFS) was 4.2 months.

For patients who failed Gemcitabine and received FOLFOX as a second-line therapy, the mPFS was 1.7 months and the ORR was 0%. For reference, the mPFS for first-line therapy in pancreatic cancer patients was 4 months.

A MedPacto representative explained, "The clinical data confirm that the combination therapy of Vactosertib and FOLFOX demonstrates significantly superior therapeutic efficacy compared to existing treatment regimens for pancreatic cancer patients."

In addition to the clinical trial of the Vactosertib and FOLFOX combination therapy, MedPacto is also conducting an investigator-initiated trial of the combination of Vactosertib and 5FU/LV/Onivyde for pancreatic cancer. This year, the company plans to apply to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial of the Vactosertib and 5FU/LV/Onivyde combination therapy for regulatory approval.

This content was produced with the assistance of AI translation services.